SOX2 and prostate cancer: Importantly, inhibition of the WNT/β-catenin pathway in enzalutamide-sensitive prostate cancer cells resulted in Enzalutamide resistance and in the acquisition of stemness properties (including OCT4, SOX2, CD44, ALDH1A, and ABCB1) [613].